<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338193</url>
  </required_header>
  <id_info>
    <org_study_id>RP-14-012</org_study_id>
    <nct_id>NCT02338193</nct_id>
  </id_info>
  <brief_title>Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women</brief_title>
  <acronym>DAPA-GDM</acronym>
  <official_title>A Randomized Study Evaluating Dapagliflozin and Metformin, Alone and in Combination, in Overweight Women With a Recent History of Gestational Diabetes Mellitus: Effects on Anthropometric Measurements and Cardiometabolic Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with a history of gestational diabetes (GDM) are at substantially increased risk of
      type 2 diabetes mellitus (T2DM). Compared with the general population, these women are more
      likely to be overweight or obese. Moreover, weight gain after GDM is significantly associated
      with T2DM, independent of baseline body weight. Weight gain, particularly increased central
      adiposity after delivery, is strongly associated with deterioration of β-cell compensation
      for insulin resistance. Taken together, our findings and other studies support increased
      abdominal fat as the strongest factor associated with declining B-cell compensation for
      insulin resistance in prior GDM women at high risk for T2DM. Dapagliflozin is a novel highly
      selective SGLT2 inhibitor that improves glycemic control by reducing renal glucose
      reabsorption leading to urinary glucose excretion. Its efficacy and safety has been studied
      in multiple randomized controlled trials including an add-on to metformin compared with a
      placebo. To the extent that glucotoxicity contributes to the demise in β-cell function in
      subjects with impaired glucose, SGLT2 inhibitors also may prove useful in the treatment of
      &quot;prediabetes.&quot; An additional secondary benefit of SGLT2 inhibition is the elimination of
      calories in the form of glucose. The loss of glucose with attendant caloric loss contributes
      to weight loss; in addition, improvements in β cell function have been seen. Weight loss seen
      with SGLT2 inhibitors is similar to that seen with glucagon-like peptide 1 analogs, and may
      be more acceptable because they are oral agents. A consistent finding in all dapagliflozin
      studies has been a reduction in blood pressure. The investigators hypothesize that
      combination dapagliflozin -metformin treatment over a 24-week period will have a greater
      positive impact on body weight, anthropometric measurements and glycemic and cardiometabolic
      parameters than dapagliflozin or metformin monotherapy in overweight/obese at-risk women with
      a history of GDM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following written consent, all study patients will undergo the following clinical, metabolic
      and laboratory evaluations before and during treatment. To ensure that patients remain
      unidentified, all study subjects will be assigned an individual study identifier which
      includes the study acronym, patient initials, and unique number. All blood samples will be
      obtained and results identified and reported using this unique study identifier. A full
      physical examination will be performed and vital signs (blood pressure, respiration and
      temperature) determined. Trained personnel using standardized protocols at the baseline and
      follow-up examination will obtain anthropometric measurements and blood specimens. Absolute
      body weight, height, waist and hip circumference, body fat distribution (waist/hip {WHR}) and
      waist/height ratio ({WHtR}) and blood pressure (BP) will be determined. Body weight will be
      measured to the nearest 0.1 kg using a calibrated digital scale with participants in light
      clothing and no shoes. Height will be measured to the nearest centimeter. The total body
      adiposity (total fatness), defined as the accumulation of body fat without regard to regional
      distribution, will be expressed as BMI and calculated as weight (kg)/ height (m) 2. The
      circumference measurements will be taken in the upright position using a 15-mm width flexible
      metric tape held close to the body but not tight enough to indent the skin. Waist
      circumference (WC) will be measured at the narrowest level midway between the lowest ribs and
      the iliac crest and hip circumference measured at the widest level over the buttocks while
      the subjects are standing and breathing normally. The WHR and WHtR will be calculated for
      measure of body fat distribution.

      All patients will randomly be assigned to one of 3 medication treatment groups--
      dapagliflozin-metformin (DAP-MET; 5 mg DAP/ MET 1000 mg BID), metformin XR (MET 1000 mg BID)
      or dapagliflozin (DAP 10 mg QD); all subjects will be allocated to one of these 3 groups
      based on computer-generated random numbers using a block randomization method. Oral glucose
      tolerance tests (OGTTs) with glucose (G) and insulin (I) measured at 0, 30, 60, and 120 after
      glucose load to assess diabetes, fasting (FBG) and mean blood glucose (MBG) concentrations,
      insulin resistance and pancreatic ß-cell function will be performed prior to randomization
      and at 20-24 weeks after full doses of study medications are reached. Mean blood glucose
      (MBG) concentrations will be calculated by summing glucose values obtained at 0,30,60 and 120
      minutes during the OGTT and dividing by 4. At the initial lab evaluation, creatinine and
      calculated eGFR, TSH, and ß-hCG will be determined for study inclusion. Baseline blood
      samples will also be analyzed for lipid profiles and liver enzymes.

      All patients will receive the same counseling concerning the benefits of lifestyle
      modification through diet and exercise. The patients will be also encouraged to increase
      daily exercise (such as walking, using stairs), although this will not be formally assessed.
      The participants will receive further encouragement to adhere to the regime during follow-up
      phone calls. Side effects of the treatment and reason for any withdrawals from the study will
      be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2015</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Change from baseline (time 0) to study end (24 weeks)</time_frame>
    <description>Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Body Weight</measure>
    <time_frame>Change from baseline (time 0) to study end (24 weeks)</time_frame>
    <description>Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (WC)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-height Ratio (WHtR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure (DBP)</measure>
    <time_frame>24 weeks of treatment)</time_frame>
    <description>Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Enzymes</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Levels (CHOL)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TRG) Levels</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose (FBG)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose (MBG) During an OGTT</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Sensitivity (HOMA-IR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Sensitivity Index (SI OGTT)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Phase Insulin Secretion (IGI/HOMA-IR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Corrected early insulin response to glucose challenge [(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)] with combination therapy compared to monotherapy after 24 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Diabetes Prevention in Women After GDM Who Are at High-risk</condition>
  <arm_group>
    <arm_group_label>DAPA/MET Extended Release (XR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapaglifloxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPA/MET XR</intervention_name>
    <description>final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
    <arm_group_label>DAPA/MET Extended Release (XR)</arm_group_label>
    <other_name>Xigduo 5mg/1000 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPA</intervention_name>
    <description>10 mg dapagliflozin QD for 20-24 weeks</description>
    <arm_group_label>Dapaglifloxin</arm_group_label>
    <other_name>Farxiga 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MET XR</intervention_name>
    <description>1000 mg Metformin XR BID for 20-24 weeks</description>
    <arm_group_label>Metformin XR</arm_group_label>
    <other_name>Glucophage XR 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Overweight/obese (BMI &gt;25) females 18 years to 45 years of age, who experienced
             gestational diabetes (GDM) during recent (within 12 months) pregnancy

               -  postpartum metabolic abnormalities determined by a 75 g oral glucose tolerance
                  test (Inclusive of prior GDM women with impaired fasting glucose (IFG), impaired
                  glucose tolerance (IGT), or both (IFG/IGT) postpartum)

               -  Completed lactation

               -  Using adequate contraception during study period unless sterilized

               -  Written consent for participation in the study

        Exclusion Criteria:

          -  Cholestasis during the past pregnancy

          -  Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of
             unknown etiology), gallstones, abnormal liver function tests or renal impairment
             (elevated serum creatinine levels or abnormal creatinine clearance

          -  Presence of significant systemic disease, heart problems including congestive heart
             failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)

          -  Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR &lt;60)

          -  Significantly elevated triglyceride levels (fasting triglyceride &gt; 400 mg %)

          -  Untreated or poorly controlled hypertension (sitting blood pressure &gt;160/95mm Hg)

          -  Prior history of a malignant disease requiring chemotherapy

          -  Known hypersensitivity or contraindications to use of insulin sensitizers such as
             metformin or thiazolidinediones

          -  History of hypersensitivity reaction to dapagliflozin or other SGLT2 inhibitors (e.g.
             anaphylaxis, angioedema, exfoliative skin conditions)

          -  Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4
             inhibitors, SGLT2 inhibitors or weight loss medications (prescription or OTC)

          -  Uncontrolled thyroid disease (documented normal TSH) or hyperprolactinemia

          -  Liver enzymes (serum alanine aminotransferase [ALT] and/or aspartate aminotransferase
             [AST] ) levels exceeding more than twice normal lab values

          -  Use of drugs known to exacerbate glucose tolerance

          -  History of diabetes or prior use of medications to treat diabetes except GDM

          -  Currently lactating

          -  Eating disorders (anorexia, bulimia) or gastrointestinal disorders

          -  Suspected pregnancy (documented negative serum pregnancy test within 72 hours before
             first dose of study drug), desiring pregnancy in next 6 months, breastfeeding, or
             known pregnancy in last 2 months

          -  Active or prior history of substance abuse (smoke or tobacco use within past 3 years)
             or significant intake of alcohol or history of alcoholism

          -  Patient not willing to use adequate contraception during study period and up to 4
             weeks after last dose of study drug (unless sterilized).

          -  Debilitating psychiatric disorder such as psychosis or neurological condition that
             might confound outcome variables

          -  Inability or refusal to comply with protocol

          -  Not currently participating or having participated in an experimental drug study in
             previous three months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Elkind-Hirsch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renee Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <results_first_submitted>March 14, 2019</results_first_submitted>
  <results_first_submitted_qc>April 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>GDM</keyword>
  <keyword>T2DM</keyword>
  <keyword>prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Will publish findings. Individual patient information will be revealed only to patient</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from Woman's Hospital post delivery</recruitment_details>
      <pre_assignment_details>3 patients not randomized since reluctant to take medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DAPA/MET XR</title>
          <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Dapaglifloxin</title>
          <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Metformin XR</title>
          <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant with visits</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved out of state</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>intolerant of side effects</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>within 1 year postpartum of GDM pregnancy</population>
      <group_list>
        <group group_id="B1">
          <title>DAPA/MET XR</title>
          <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Dapaglifloxin</title>
          <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Metformin XR</title>
          <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI greater than/equal to 25</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight</title>
        <description>Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24</description>
        <time_frame>Change from baseline (time 0) to study end (24 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.5" spread="14"/>
                    <measurement group_id="O2" value="-12.5" spread="20"/>
                    <measurement group_id="O3" value="-4.4" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One Way ANOVA with Bonferroni contrast if p&gt;0.05</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.032</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Body Weight</title>
        <description>Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24</description>
        <time_frame>Change from baseline (time 0) to study end (24 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Body Weight</title>
          <description>Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24</description>
          <units>percent weight loss from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="3.1"/>
                    <measurement group_id="O2" value="-3.2" spread="4.5"/>
                    <measurement group_id="O3" value="-1.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>One Way ANOVA with Bonferoni contrast test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="6.2"/>
                    <measurement group_id="O2" value="33.7" spread="7.7"/>
                    <measurement group_id="O3" value="31" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference (WC)</title>
        <description>Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference (WC)</title>
          <description>Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" spread="12.7"/>
                    <measurement group_id="O2" value="95" spread="16.6"/>
                    <measurement group_id="O3" value="91.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.012</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)</title>
        <description>Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)</title>
          <description>Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.055"/>
                    <measurement group_id="O2" value="0.80" spread=".06"/>
                    <measurement group_id="O3" value="0.83" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to-height Ratio (WHtR)</title>
        <description>Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to-height Ratio (WHtR)</title>
          <description>Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread=".06"/>
                    <measurement group_id="O2" value="0.57" spread=".09"/>
                    <measurement group_id="O3" value="0.56" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure (DBP)</title>
        <description>Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure (DBP)</title>
          <description>Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="11"/>
                    <measurement group_id="O2" value="77.8" spread="11"/>
                    <measurement group_id="O3" value="79" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP)</title>
        <description>Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <description>Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="12"/>
                    <measurement group_id="O2" value="124" spread="13"/>
                    <measurement group_id="O3" value="119.6" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Enzymes</title>
        <description>ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Enzymes</title>
          <description>ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread=".35"/>
                    <measurement group_id="O2" value="1.12" spread=".32"/>
                    <measurement group_id="O3" value="1.18" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Levels (CHOL)</title>
        <description>Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Levels (CHOL)</title>
          <description>Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" spread="45"/>
                    <measurement group_id="O2" value="168" spread="32"/>
                    <measurement group_id="O3" value="178" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride (TRG) Levels</title>
        <description>Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride (TRG) Levels</title>
          <description>Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="59"/>
                    <measurement group_id="O2" value="89.8" spread="39"/>
                    <measurement group_id="O3" value="212" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.004</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose (FBG)</title>
        <description>Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose (FBG)</title>
          <description>Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" spread="7.9"/>
                    <measurement group_id="O2" value="91" spread="9.2"/>
                    <measurement group_id="O3" value="87" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose (MBG) During an OGTT</title>
        <description>Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose (MBG) During an OGTT</title>
          <description>Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.5" spread="15.2"/>
                    <measurement group_id="O2" value="110.1" spread="17.8"/>
                    <measurement group_id="O3" value="112.5" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.012</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin Sensitivity (HOMA-IR)</title>
        <description>HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin Sensitivity (HOMA-IR)</title>
          <description>HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.6"/>
                    <measurement group_id="O2" value="2.4" spread="1.4"/>
                    <measurement group_id="O3" value="1.8" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Sensitivity Index (SI OGTT)</title>
        <description>Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Sensitivity Index (SI OGTT)</title>
          <description>Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="3.2"/>
                    <measurement group_id="O2" value="6.3" spread="4.4"/>
                    <measurement group_id="O3" value="5.42" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.028</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Phase Insulin Secretion (IGI/HOMA-IR)</title>
        <description>Corrected early insulin response to glucose challenge [(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)] with combination therapy compared to monotherapy after 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DAPA/MET XR</title>
            <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dapaglifloxin</title>
            <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Metformin XR</title>
            <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase Insulin Secretion (IGI/HOMA-IR)</title>
          <description>Corrected early insulin response to glucose challenge [(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)] with combination therapy compared to monotherapy after 24 weeks of treatment</description>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.2"/>
                    <measurement group_id="O2" value="1.1" spread="1.2"/>
                    <measurement group_id="O3" value="0.77" spread=".53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.03</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months while participating in trial</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DAPA/MET XR</title>
          <description>Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
DAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Dapaglifloxin</title>
          <description>Dapagliflozin- 10 mg once daily before first meal for 24 weeks
DAPA: 10 mg dapagliflozin QD for 20-24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Metformin XR</title>
          <description>Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
MET XR: 1000 mg Metformin XR BID for 20-24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Yeast infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Important limitations were the small number completed patients per drug group and only 24 weeks of therapy. Surrogate measures were for central adiposity; use of dual-energy x-ray absorptiometry to measure body composition would increase accuracy</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen Elkind-Hirsch, Director of Research</name_or_title>
      <organization>Woman's Hospital</organization>
      <phone>225 231-5278</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

